Bottom line
How much do XBI and FBTAX overlap?
21% of their top holdings overlap by weight. 7 securities appear in both funds' top 25, making up 8.7% of XBI's assets and 18.0% of FBTAX's. They are substantially different portfolios, so owning both adds real diversification.
Updated Nov 22, 2026
Overlap at a glance
Holdings XBI and FBTAX have in common
| Holding | % of XBI | % of FBTAX | Overlap |
|---|---|---|---|
| Moderna Inc | 1.41% | 1.60% | 1.41% |
| Oruka Therapeutics Inc | 1.38% | 3.24% | 1.38% |
| Revolution Medicines Inc | 1.20% | 3.00% | 1.20% |
| Vaxcyte Inc | 1.19% | 1.97% | 1.19% |
| Dianthus Therapeutics Inc | 1.18% | 3.55% | 1.18% |
| Natera Inc | 1.16% | 1.43% | 1.16% |
| Cogent Biosciences Inc | 1.14% | 3.25% | 1.14% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in XBI
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Twist Bioscience Corp — 1.41%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Rhythm Pharmaceuticals Inc — 1.20%
- CG oncology Inc — 1.20%
- SELLAS Life Sciences Group Inc — 1.19%
- Cytokinetics Inc — 1.18%
- Scholar Rock Holding Corp — 1.16%
- Roivant Sciences Ltd — 1.16%
- Mirum Pharmaceuticals Inc — 1.16%
- Ultragenyx Pharmaceutical Inc — 1.14%
Only in FBTAX
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Insmed Inc — 3.05%
- Argenx Se — 3.00%
- Ascendis Pharma A/s — 2.99%
- Biogen Inc — 2.71%
- Mbx Biosciences Inc — 2.45%
- Amgen Inc — 2.37%
- Amylyx Pharmaceuticals Inc — 2.25%
- Fidelity Revere Street Trust — 1.96%
- Relay Therapeutics Inc — 1.58%
- Viridian Therapeutics Inc — 1.53%
- Kiniksa Pharmaceuticals International Plc — 1.41%
Asset mix
| Asset type | XBI | FBTAX |
|---|---|---|
| Stocks | 99.9% | 98.2% |
| Cash & short-term funds | 5.9% | 2.4% |
| Preferred stock | — | 1.5% |
| Bonds | — | 0.1% |
| Equity derivatives | 0.1% | — |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Country mix
| Country | XBI | FBTAX |
|---|---|---|
| US | 100.8% | 87.8% |
| NL | 1.0% | 4.3% |
| DK | — | 3.0% |
| KY | — | 1.8% |
| GB | — | 1.8% |
| CA | 0.2% | 1.4% |
| IE | 1.2% | — |
| BM | 1.2% | 1.2% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do XBI and FBTAX overlap?
What stocks do XBI and FBTAX have in common?
Should I own both XBI and FBTAX?
Which holds more stocks, XBI or FBTAX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.